Catalyst Event
Bristol-Myers Squibb Co (BMY) · Other
From Akros U.S. High Dividend 20 Index (AUHDIV20)
5/29/2026, 12:00:00 AM
Announced positive Phase 3 SUCCESSOR-2 trial results on 2026-05-29 showing a 52% reduction in disease progression risk for multiple myeloma. This breakthrough is estimated to have a >10% price impact expected.
Korean Translation
2026년 5월 29일, 다발성 골수종 환자의 질병 진행 위험을 52% 감소시킨 3상 SUCCESSOR-2 임상 결과를 발표함. 획기적인 임상 결과로 10% 이상의 주가 영향이 예상됨.
Related Recent Events
Canadian Natural Resources Ltd (CNQ.) · Earnings Release
Low importance estimated as the announcement of a reporting date typically has minimal immediate price impact; Q2 2026 earnings release is scheduled.
8/6/2026, 12:00:00 AM
Manulife Financial Corp (MFC) · Earnings Release
Manulife is scheduled to release its Q2 2026 financial results after the market close on August 5, 2026; market reaction is estimated as High (>=10%) given historical volatility around earnings, scheduled.
8/5/2026, 12:00:00 AM
Bristol-Myers Squibb Co (BMY) · Earnings Release
Q2 2026 earnings results are scheduled to be released on 2026-07-30. A market reaction of >1% is estimated upon the actual release scheduled.
7/30/2026, 12:00:00 AM
Comcast Corp (CMCSA) · Earnings Release
Q2 2026 earnings release is scheduled.
7/30/2026, 12:00:00 AM
Mondelez International Inc (MDLZ) · Earnings Release
The company's Q2 2026 earnings release is scheduled.
7/28/2026, 12:00:00 AM
AT&T Inc (T) · Earnings Release
The second-quarter 2026 earnings release for July 22, 2026, is scheduled; importance is estimated at Low as earnings typically drive at least 1% price movement, scheduled.
7/22/2026, 12:00:00 AM